Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Devonian Health Group Inc DVHGF


Primary Symbol: V.GSD

Healthcare
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution... see more

Recent & Breaking News (TSXV:GSD)

Devonian Health Group Announces Its Participation at BIO-Partnering During JP Morgan Healthcare Conference 2022, Being Held Virtually on January 10 to 14, 2022.

Business Wire November 4, 2021

Devonian Health Group Announces Appointment of Martin Moreau as Vice-President Finance and as a New Member of its Board of Directors

Business Wire September 30, 2021

Devonian Health Group Announces Closing of a Private Placement

Business Wire September 13, 2021

Devonian Announces the Issuance of Units in Settlement of Interests Owed to Debenture Holders

Business Wire September 8, 2021

Devonian Health Group Announces Exclusive Distribution, Sales and Marketing Agreement for Purgenesis(TM) Anti-aging Products in Middle East Countries

Business Wire August 31, 2021

Devonian Health Group Inc. Announces Its Participation at Virtual BioPlus-Interphex Korea 2021 to Take Place From August 31st to September 15, 2021

Business Wire August 26, 2021

Devonian Announces the Issuance of Units in Settlement of Interests Owed to a Debenture Holder

Business Wire July 27, 2021

Devonian Heath Group Inc. to Participate in Renmark's Virtual Non-deal Roadshow Series in Chicago (USA) Today July 27, 2021

Business Wire July 27, 2021

Devonian Heath Group Inc. to Participate in Renmark's Virtual Non-deal Roadshow Series in Los Angeles (USA) Today July 20, 2021

Business Wire July 20, 2021

Devonian Heath Group Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series for Vancouver Today June 14, 2021

Business Wire June 14, 2021

Devonian Heath Group Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series for Montreal and East of Canada Today June 3rd, 2021

Business Wire June 3, 2021

Devonian Heath Group Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series in Boston (USA) Today, May 26, 2021

Business Wire May 26, 2021

Devonian Heath Group Inc. to Present at the Canada India Healthcare Summit 2021

Business Wire May 13, 2021

Devonian Heath Group Inc. to Participate in Renmark's Virtual Non-deal Roadshow Series on Thursday, May 13, 2021

Business Wire May 11, 2021

Devonian Health Group Inc. Retains Renmark Financial Communications Inc. to Provide Investor Relations Services

Business Wire April 14, 2021

Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine(TM) for the Treatment of Cardiovascular Diseases.

Business Wire March 30, 2021

Devonian Health Group Provides More Details on Previously Announced Positive Topline Results From Phase 2 Clinical Trial of Thykamine(TM) in Adult Population with Mild-to-Moderate Atopic Dermatitis and the Grant of Stock Options.

Business Wire March 25, 2021

Devonian Announces the Issuance of Units in Settlement of Interests Owed to Debenture Holders

Business Wire March 5, 2021

Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine(TM) in Adult Patients with Mild-to-Moderate Atopic Dermatitis.

Business Wire February 18, 2021

Devonian Health Group Announces Voting Results of The Annual General and Special Meeting

Business Wire January 28, 2021